Given the aforementioned information and the lack of therapies targeting MUC4, we proposed that TNFα-blocking agents or MUC4-targeted therapies in combination with immunotherapy and the standard of care for each cancer type should be further investigated in the clinical setting. Here, MUC4 is linked to cancer.